Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

WuXi Biologics Completes GMP Inspection by Health Canada for Drug Substance Facility

Thursday, October 28, 2021

WuXi Biologics, a global company with leading open-access biologics technology platforms, announced that it has completed a remote GMP inspection by Health Canada for its drug substance facility (MFG2) in Wuxi city. There were no observations during the inspection, demonstrating that the company's premier quality system is in full compliance with global regulatory requirements.

The comprehensive inspection was conducted by three inspectors and covered the facility's quality processes and entire production system. So far, WuXi Biologics has successfully completed nearly 20 regulatory inspections conducted by eight different agencies including the U.S. FDA, EMA and NMPA, 13 of which were conducted this year.

"We are very proud of successfully completing another regulatory inspection," said Dr. Chris Chen, CEO of WuXi Biologics. "Our world-class quality system being certified by various regulatory agencies in the U.S., EU, China, Japan, Brazil, and Singapore is a strong testament to our commitment to maintaining the highest global quality standards. With those standards as our cornerstone, WuXi Biologics will continue to enable our global partners to provide life-saving treatments quickly and effectively to benefit patients worldwide."

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024